Wed, Apr 16, 2014, 12:36 PM EDT - U.S. Markets close in 3 hrs 24 mins

Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • downbythewater@ymail.com downbythewater Apr 18, 2013 10:29 AM Flag

    REAL antibiotic NEWS ! ========== Forrest labs antibiotic

    idiots here talking about an old antibiotic with a new machine.

    Forest Labs, Almirall Reveal Positive Late-stage Results For Aclidinium/Formoterol

    Alarmingly Slow Progress In Antibiotic Development: IDSA
    U.S. Drug manufacturer Forest Laboratories Inc. (FRX: Quote) and Spanish pharmaceutical company Almirall, S.A Tuesday announced positive results form a six month phase III trial evaluating fixed doze combinations of aclidinium bromide, and formoterol fumarate delivered by Almirall's inhaler Genuair, Pressair in the USA.
    COPD, or chronic obstructive pulmonary disease, is a common, progressive, and debilitating lung disease characterized by persistent airflow limitation that makes it hard to breathe

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Were you looking in the mirror when you wrote your message!

    • These are bronchiodilators. Did you read the article? They are not antibiotics.

      Sentiment: Strong Buy

    • downbythewater@ymail.com downbythewater Apr 18, 2013 10:32 AM Flag

      Teflaro was approved in October 2010 to treat adults with community acquired bacterial pneumonia and acute bacterial skin and skin structure infections, or ABSSSI, including methicillin-resistant Staphylococcus aureus.
      Last month, the CDC warned of a growing prevalence of carbapenem-resistant Enterobacteriaceae, or CRE, at U.S. hospitals.
      CRE, which belong to a family of gram-negative bacilli bacteria are nightmare bacteria because it is resistant to even the strongest antibiotic available and patients are left with potentially untreatable infections, said Tom Frieden, Director of the Centers for Disease Control and Prevention, last month.
      A new report, published online on April 18 in Clinical Infectious Diseases says that there are only seven new drugs in development for the treatment of infections caused by multidrug-resistant gram-negative bacilli, or GNB, bacteria.
      But will any of the drugs currently in development to treat GNB pass muster with FDA? Even if approved, will these drugs be effective against the most resistant bugs that everyone is worried about? These are questions only time will answer, says the report.
      Henry Chambers, MD, chair of IDSA's Antimicrobial Resistance Committee, or ARC, said, "In the past, the 10 x '20 goal would have been considered modest, but today the barriers to approval of nine additional antibiotics by 2020 seem insurmountable."

      • 1 Reply to downbythewater
      • Arikace will have at least one approval by mid-2014, if not both. I am hoping for NTM.

        These sidebars that you are presenting have nothing to do with Arikace. Meth resistant Sa and Enterobacteriacae are Gram positive. Entero has replaced fecal coliforms as the marker of fecal contamination of drinking or swimming water.

        Off point on both "news" items.

        Sentiment: Strong Buy

 
INSM
12.65+0.08(+0.64%)12:36 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.